COMMUNIQUÉS West-GlobeNewswire
      -   
  
Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025 -   
  
BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders
14/05/2025 -   
  
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
14/05/2025 -   
  
3Daughters Selects Connect Labs by Wexford - Baltimore for New Corporate Headquarters
14/05/2025 -   
  
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer
14/05/2025 -   
  
INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference
14/05/2025 -   
  
Targeted Genomics Announces Commercial Collaboration with OraSure Technologies for Direct to Consumer (DTC) Celiac Genetic Testing
14/05/2025 -   
  
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
14/05/2025 -   
  
Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo Models
14/05/2025 -   
  
Hydreight Technologies to Present at Maxim Group’s 2025 Virtual Tech Conference & the CEM Bermuda Capital Event
14/05/2025 -   
  
Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
14/05/2025 -   
  
HEKA AI Mattress Named “Best Overall SleepTech Solution” in 2025 MedTech Breakthrough Awards Program
14/05/2025 -   
  
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025 -   
  
IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025
14/05/2025 -   
  
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
14/05/2025 -   
  
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program
14/05/2025 -   
  
A comparative sNPWT study of 10,000+ C-sections shows PICO™ sNPWT reduces complications and cuts healthcare costs by $728,000 per 1,000 patients
14/05/2025 -   
  
Glass House Brands and LEEF Announce MSA for The Leaf El Paseo Dispensary and Off-Take Agreement
14/05/2025 -   
  
Emergent BioSolutions to Participate in Upcoming Investor Conferences
14/05/2025 
Pages